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Background
Food allergies constitutes an important global health
issue for the allergic consumers, the food industry and de
medical health care. Since no treatment for food allergy
is yet available, the allergic patient should completely
avoid the threatening allergens from his diet. This is not
easy to achieve in practice because the allergic consumer
can already have an allergic reaction after eating traces of
relevant allergens due to cross-contamination. This is the
reason why many food manufactures make more and
more use of precautionary labels such as ‘may contain
traces of...’ To deal with this, there is an urgent need for
analytical methods than can be used in food industries
which should be highly specific and sensitive, detecting
traces of allergens and be rapid, robust, reliable and cost-
effective. For this moment, immunoassays are the most
preferred method but there are only a limited number
validated for only a few food allergens so research in this
regard is still needed. Which allergenic compounds to
detect and their change in allergenic potential during
food processing are examples of important issues to be
taken into consideration.
The main focus of this project is the generation of
relevant monoclonal recombinant antibodies against
hazelnuts which are patient-dependent and/or highly
specific. Hazelnuts are widely used in the food industry
and belong to one of the most important food allergens.
Methods
Purified antigens were received from the EAACI group in
Vienna (Cor a 1 and Cor a 8). First the purified antigens
were used to generate highly specific nanobodies (VIB
Nanobody Service Facility-VUB, Brussels) which still
need to be further validated. These antibody fragments
are interesting because of their high target specificity and
–affinity, ease of manufacturing and excellent stability. In
a second approach recombinant antibodies will be devel-
oped starting from the genetic information present in the
blood of clinically characterized hazelnut allergic patients
(scFv-fragments).
Results
In the nanobody approach, the VHH-library was prepared
(library size = 10^8 ) and selective panning rounds are cur-
rently being carried out. For the second approach, Cor a 1
and Cor a 8 patients were selected. Currently blood collec-
tion, mRNA isolation and cDNA preparation are planned.
Conclusion
We believe that this approach can result in different
antibody fragments valuable for a specific and sensitive
detection of food allergens.
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